To further validate that CRABP1 can be a useful therapeutic target in managing pathological conditions caused by CaMKII over-activation, we recently carefully examined the ALS-like motor deterioration phenotype of CKO mice and the mechanism of CRABP1 action in the motor system [10]. This evidence concerns the gene CRABP1 and amyotrophic lateral sclerosis.